News & Events

and the attached Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

and in the attached Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Regulation FD Disclosure. On February 5, 2026, the Company declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on June 2, 2026, to all holders of record of the Company’s common stock as of the close of business on April 20, 2026. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Secu…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective April 16, 2024, Heidi C. Chen will cease her role as Executive Vice President, General Counsel and Corporate Secretary, and Business Lead of Human Health Diagnostics of Zoetis Inc. (the “Company”). Ms. Chen will continue as an employee advisor of the Company through July 16, 2024, after which time it is anticipated she will serve as a non…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 5, 2023, Zoetis terminated Glenn David, Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices at Zoetis Inc. (the “Company”), for violating company policy by engaging in a consensual personal relationship and failing to disclose it to the Company. Mr. David’s conduct did not impact our consolid…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Zoetis Inc. (the “Company”) appointed Glenn David as the Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, effective November 1, 2022. Glenn David currently serves as Executive Vice President and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance. As a result of these…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 19, 2022, Mr. Roman Trawicki, the Executive Vice President and President, Global Manufacturing and Supply at Zoetis Inc. (the “Company”) provided notice of his intention to retire from the Company. The retirement will be effective as of July 31, 2022. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the regist…